An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Fimasartan (Primary)
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 22 Jan 2025 Status changed from not yet recruiting to active, no longer recruiting.
- 25 Dec 2024 New trial record